Lead (Pb) and the Risk of Alzheimer’s disease or cognitive decline: A systematic review

References

• Ahamed M, Siddiqui MK. (2007). Low level lead exposure and oxidative stress: current opinions. Clin Chim Acta, 383, 57–64.
   PubMed Web of Science ®Google Scholar
• Alzheimer’s Disease International. (2009). World Alzheimer Report [Online]. Available: http://www.alz.co.uk/research/files/WorldAlzheimerReport.pdf [Accessed 01.09.2010].
   Google Scholar
• Alzheimer’s Disease International. (2010). World Alzheimer Report [Online]. Available: http://www.alz.org/documents/national/World_Alzheimer_Report_2010.pdf [Accessed 01.12.2010].
   Google Scholar
• Angelo RT, Cringan MS, Chamberlain DL, Stahl AJ, Haslouer SG, Goodrich CA. (2007). Residual effects of lead and zinc mining on freshwater mussels in the Spring River Basin (Kansas, Missouri, and Oklahoma, USA). Sci Total Environ, 384, 467–496.
   PubMed Web of Science ®Google Scholar
• Atkins DS, Basha MR, Zawia NH. (2003). Intracellular signaling pathways involved in mediating the effects of lead on the transcription factor Sp1. Int J Dev Neurosci, 21, 235–244.
   PubMed Web of Science ®Google Scholar
• Ballatore C, Lee VM, Trojanowski JQ. (2007). Tau-mediated neurodegeneration in Alzheimer’s disease and related disorders. Nat Rev Neurosci, 8, 663–672.
   PubMed Web of Science ®Google Scholar
• Basha MR, Murali M, Siddiqi HK, Ghosal K, Siddiqi OK, Lashuel HA, Ge YW, Lahiri DK, Zawia NH. (2005). Lead (Pb) exposure and its effect on APP proteolysis and Abeta aggregation. FASEB J, 19, 2083–2084.
   PubMedGoogle Scholar
• Basha MR, Wei W, Brydie M, Razmiafshari M, Zawia NH. (2003). Lead-induced developmental perturbations in hippocampal Sp1 DNA-binding are prevented by zinc supplementation: in vivo evidence for Pb and Zn competition. Int J Dev Neurosci, 21, 1–12.
   PubMed Web of Science ®Google Scholar
• Basha MR, Wei W, Bakheet SA, Benitez N, Siddiqi HK, Ge YW, Lahiri DK, Zawia NH. (2005). The fetal basis of amyloidogenesis: exposure to lead and latent overexpression of amyloid precursor protein and beta-amyloid in the aging brain. J Neurosci, 25, 823–829.
   PubMed Web of Science ®Google Scholar
• Basun H, Forssell LG, Wetterberg L, Winblad B. (1991). Metals and trace elements in plasma and cerebrospinal fluid in normal aging and Alzheimer’s disease. J Neural Transm Park Dis Dement Sect, 3, 231–258.
   PubMedGoogle Scholar
• Behl M, Zhang Y, Zheng W. (2009). Involvement of insulin-degrading enzyme in the clearance of beta-amyloid at the blood-CSF barrier: Consequences of lead exposure. Cerebrospinal Fluid Res, 6, 11.
   PubMedGoogle Scholar
• Behl M, Zhang Y, Monnot AD, Jiang W, Zheng W. (2009). Increased beta-amyloid levels in the choroid plexus following lead exposure and the involvement of low-density lipoprotein receptor protein-1. Toxicol Appl Pharmacol, 240, 245–254.
   PubMed Web of Science ®Google Scholar
• Behl M, Zhang Y, Shi Y, Cheng J, Du Y, Zheng W. (2010). Lead-induced accumulation of beta-amyloid in the choroid plexus: role of low density lipoprotein receptor protein-1 and protein kinase C. Neurotoxicology, 31, 524–532.
   PubMed Web of Science ®Google Scholar
• Berlin D, Chong G, Chertkow H, Bergman H, Phillips NA, Schipper HM. (2004). Evaluation of HFE (hemochromatosis) mutations as genetic modifiers in sporadic AD and MCI. Neurobiol Aging, 25, 465–474.
   PubMed Web of Science ®Google Scholar
• Bertram L, Lill CM, Tanzi RE. (2010). The genetics of Alzheimer disease: back to the future. Neuron, 68, 270–281.
   PubMed Web of Science ®Google Scholar
• Bolin CM, Basha R, Cox D, Zawia NH, Maloney B, Lahiri DK, Cardozo-Pelaez F. (2006). Exposure to lead and the developmental origin of oxidative DNA damage in the aging brain. FASEB J, 20, 788–790.
   PubMed Web of Science ®Google Scholar
• Braak H, Braak E. (1991). Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol, 82, 239–259.
   PubMed Web of Science ®Google Scholar
• Casas JS& Sordo, J. 2006. An overview of the historical importance, occurance, isolation, properties and applications of lead. In: Casas JS& Sordo J. (eds.) Lead. Amsterdam: Elsevier.
   Google Scholar
• Christensen MA, Zhou W, Qing H, Lehman A, Philipsen S, Song W. (2004). Transcriptional regulation of BACE1, the beta-amyloid precursor protein beta-secretase, by Sp1. Mol Cell Biol, 24, 865–874.
   PubMed Web of Science ®Google Scholar
• Citron BA, Dennis JS, Zeitlin RS, Echeverria V. (2008). Transcription factor Sp1 dysregulation in Alzheimer’s disease. J Neurosci Res, 86, 2499–2504.
   PubMed Web of Science ®Google Scholar
• Cory-Slechta DA. (1997). Relationships between Pb-induced changes in neurotransmitter system function and behavioral toxicity. Neurotoxicology, 18, 673–688.
   Google Scholar
• Crossgrove JS, Li GJ, Zheng W. (2005). The choroid plexus removes beta-amyloid from brain cerebrospinal fluid. Exp Biol Med (Maywood), 230, 771–776.
   Google Scholar
• Davey FD, Breen KC. (1998). The interaction between chronic low-level lead and the amyloid beta precursor protein. Amyloid, 5, 90–98.
   PubMed Web of Science ®Google Scholar
• De La Monte SM& Wands JR (2008). Alzheimer’s disease is type 3 diabetes-evidence reviewed. J Diabetes Sci Technol (Online), 2, 1101–1113.
   PubMedGoogle Scholar
• Deane R, Du Yan S, Submamaryan RK, LaRue B, Jovanovic S, Hogg E, Welch D, Manness L, Lin C, Yu J, Zhu H, Ghiso J, Frangione B, Stern A, Schmidt AM, Armstrong DL, Arnold B, Liliensiek B, Nawroth P, Hofman F, Kindy M, Stern D, Zlokovic B. (2003). RAGE mediates amyloid-beta peptide transport across the blood-brain barrier and accumulation in brain. Nat Med, 9, 907–913.
   PubMed Web of Science ®Google Scholar
• Devi CB, Reddy GH, Prasanthi RP, Chetty CS, Reddy GR. (2005). Developmental lead exposure alters mitochondrial monoamine oxidase and synaptosomal catecholamine levels in rat brain. Int J Dev Neurosci, 23, 375–381.
   PubMed Web of Science ®Google Scholar
• Devoto P, Flore G, Ibba A, Fratta W, Pani L. (2001). Lead intoxication during intrauterine life and lactation but not during adulthood reduces nucleus accumbens dopamine release as studied by brain microdialysis. Toxicol Lett, 121, 199–206.
   Google Scholar
• Donahue JE, Flaherty SL, Johanson CE, Duncan JA 3rd, Silverberg GD, Miller MC, Tavares R, Yang W, Wu Q, Sabo E, Hovanesian V, Stopa EG. (2006). RAGE, LRP-1, and amyloid-beta protein in Alzheimer’s disease. Acta Neuropathol, 112, 405–415.
   PubMed Web of Science ®Google Scholar
• Egerházi A, Berecz R, Bartók E, Degrell I. (2007). Automated Neuropsychological Test Battery (CANTAB) in mild cognitive impairment and in Alzheimer’s disease. Prog Neuropsychopharmacol Biol Psychiatry, 31, 746–751.
   PubMed Web of Science ®Google Scholar
• Engle MJ, Volpe JJ. (1990). Glutamine synthetase activity of developing astrocytes is inhibited in vitro by very low concentrations of lead. Brain Res Dev Brain Res, 55, 283–287.
   PubMedGoogle Scholar
• Ercal N, Gurer-Orhan H, Aykin-Burns N. (2001). Toxic metals and oxidative stress part I: mechanisms involved in metal-induced oxidative damage. Curr Top Med Chem, 1, 529–539.
   PubMedGoogle Scholar
• Farris W, Mansourian S, Chang Y, Lindsley L, Eckman EA, Frosch MP, Eckman CB, Tanzi RE, Selkoe DJ, Guenette S. (2003). Insulin-degrading enzyme regulates the levels of insulin, amyloid beta-protein, and the beta-amyloid precursor protein intracellular domain in vivo. Proc Natl Acad Sci USA, 100, 4162–4167.
   PubMed Web of Science ®Google Scholar
• Flicker L. (2010). Modifiable lifestyle risk factors for Alzheimer’s disease. J Alzheimers Dis, 20, 803–811.
   PubMedGoogle Scholar
• Forette F, Seux ML, Staessen JA, Thijs L, Birkenhäger WH, Babarskiene MR, Babeanu S, Bossini A, Gil-Extremera B, Girerd X, Laks T, Lilov E, Moisseyev V, Tuomilehto J, Vanhanen H, Webster J, Yodfat Y, Fagard R. (1998). Prevention of dementia in randomised double-blind placebo-controlled Systolic Hypertension in Europe (Syst-Eur) trial. Lancet, 352, 1347–1351.
   PubMed Web of Science ®Google Scholar
• Gerhardsson L, Blennow K, Lundh T, Londos E, Minthon L. (2009). Concentrations of metals, beta-amyloid and tau-markers in cerebrospinal fluid in patients with Alzheimer’s disease. Dement Geriatr Cogn Disord, 28, 88–94.
   PubMed Web of Science ®Google Scholar
• Gerhardsson L, Lundh T, Minthon L, Londos E. (2008). Metal concentrations in plasma and cerebrospinal fluid in patients with Alzheimer’s disease. Dement Geriatr Cogn Disord, 25, 508–515.
   PubMed Web of Science ®Google Scholar
• Gläser C, Schulz S, Handschug K, Huse K, Birkenmeier G. (2004). Genetic and functional characteristics of the human in vivo LRP1/A2MR receptor suggested as a risk marker for Alzheimer’s disease and other complex (degenerative) diseases. Neurosci Res, 50, 85–101.
   Google Scholar
• Glass TA, Bandeen-Roche K, McAtee M, Bolla K, Todd AC, Schwartz BS. (2009). Neighborhood psychosocial hazards and the association of cumulative lead dose with cognitive function in older adults. Am J Epidemiol, 169, 683–692.
   PubMed Web of Science ®Google Scholar
• Godwin HA. (2001). The biological chemistry of lead. Curr Opin Chem Biol, 5, 223–227.
   PubMed Web of Science ®Google Scholar
• Goldstein GW. (1993). Evidence that lead acts as a calcium substitute in second messenger metabolism. Neurotoxicology, 14, 97–101.
   PubMed Web of Science ®Google Scholar
• Gong Z, Evans HL. (1997). Effect of chelation with meso-dimercaptosuccinic acid (DMSA) before and after the appearance of lead-induced neurotoxicity in the rat. Toxicol Appl Pharmacol, 144, 205–214.
   PubMedGoogle Scholar
• Grandjean P, Kon SH. (1981). Lead exposure of welders and bystanders in a ship repair yard. Am J Ind Med, 2, 65–70.
   PubMedGoogle Scholar
• Green RC, Cupples LA, Kurz A, Auerbach S, Go R, Sadovnick D, Duara R, Kukull WA, Chui H, Edeki T, Griffith PA, Friedland RP, Bachman D, Farrer L. (2003). Depression as a risk factor for Alzheimer disease: the MIRAGE Study. Arch Neurol, 60, 753–759.
   PubMed Web of Science ®Google Scholar
• Gu H, Wei X, Monnot AD, Fontanilla CV, Behl M, Farlow MR, Zheng W, Du Y. (2011). Lead exposure increases levels of ß-amyloid in the brain and CSF and inhibits LRP1 expression in APP transgenic mice. Neurosci Lett, 490, 16–20.
   PubMed Web of Science ®Google Scholar
• Gu Y, Nieves JW, Stern Y, Luchsinger JA, Scarmeas N. (2010). Food combination and Alzheimer disease risk: a protective diet. Arch Neurol, 67, 699–706.
   PubMed Web of Science ®Google Scholar
• Guilarte TR, Toscano CD, McGlothan JL, Weaver SA. (2003). Environmental enrichment reverses cognitive and molecular deficits induced by developmental lead exposure. Ann Neurol, 53, 50–56.
   PubMed Web of Science ®Google Scholar
• Hampel H, Frank R, Broich K, Teipel SJ, Katz RG, Hardy J, Herholz K, Bokde AL, Jessen F, Hoessler YC, Sanhai WR, Zetterberg H, Woodcock J, Blennow K. (2010). Biomarkers for Alzheimer’s disease: academic, industry and regulatory perspectives. Nat Rev Drug Discov, 9, 560–574.
   PubMed Web of Science ®Google Scholar
• Hanson EH, Imperatore G, Burke W. (2001). HFE gene and hereditary hemochromatosis: a HuGE review. Human Genome Epidemiology. Am J Epidemiol, 154, 193–206.
   PubMed Web of Science ®Google Scholar
• Haraguchi T, Ishizu H, Takehisa Y, Kawai K, Yokota O, Terada S, Tsuchiya K, Ikeda K, Morita K, Horike T, Kira S, Kuroda S. (2001). Lead content of brain tissue in diffuse neurofibrillary tangles with calcification (DNTC): the possibility of lead neurotoxicity. Neuroreport, 12, 3887–3890.
   PubMed Web of Science ®Google Scholar
• Hardy J, Selkoe DJ. (2002). The amyloid hypothesis of Alzheimer’s disease: progress and problems on the road to therapeutics. Science, 297, 353–356.
   PubMed Web of Science ®Google Scholar
• Hebert LE, Scherr PA, Bienias JL, Bennett DA, Evans DA. (2003). Alzheimer disease in the US population: prevalence estimates using the 2000 census. Arch Neurol, 60, 1119–1122.
   PubMed Web of Science ®Google Scholar
• Heicklen-Klein A, Ginzburg I. (2000). Tau promoter confers neuronal specificity and binds Sp1 and AP-2. J Neurochem, 75, 1408–1418.
   Google Scholar
• Hensley K, Carney JM, Mattson MP, Aksenova M, Harris M, Wu JF, Floyd RA, Butterfield DA. (1994). A model for beta-amyloid aggregation and neurotoxicity based on free radical generation by the peptide: relevance to Alzheimer disease. Proc Natl Acad Sci USA, 91, 3270–3274.
   PubMed Web of Science ®Google Scholar
• Hernberg S. (2000). Lead poisoning in a historical perspective. Am J Ind Med, 38, 244–254.
   PubMed Web of Science ®Google Scholar
• Herz J, Chen Y, Masiulis I, Zhou L. (2009). Expanding functions of lipoprotein receptors. J Lipid Res, 50 Suppl, S287–S292.
   Google Scholar
• Herz J, Strickland DK. (2001). LRP: a multifunctional scavenger and signaling receptor. J Clin Invest, 108, 779–784.
   PubMed Web of Science ®Google Scholar
• Hirtz D, Thurman DJ, Gwinn-Hardy K, Mohamed M, Chaudhuri AR, Zalutsky R. (2007). How common are the “common” neurologic disorders? Neurology, 68, 326–337.
   PubMed Web of Science ®Google Scholar
• Holsinger RM, McLean CA, Beyreuther K, Masters CL, Evin G. (2002). Increased expression of the amyloid precursor beta-secretase in Alzheimer’s disease. Ann Neurol, 51, 783–786.
   PubMed Web of Science ®Google Scholar
• Hu H, Payton M, Korrick S, Aro A, Sparrow D, Weiss ST, Rotnitzky A. (1996). Determinants of bone and blood lead levels among community-exposed middle-aged to elderly men. The normative aging study. Am J Epidemiol, 144, 749–759.
   PubMed Web of Science ®Google Scholar
• Hu H, Shih R, Rothenberg S, Schwartz BS. (2007). The epidemiology of lead toxicity in adults: measuring dose and consideration of other methodologic issues. Environ Health Perspect, 115, 455–462.
   PubMed Web of Science ®Google Scholar
• Jankowsky JL, Melnikova T, Fadale DJ, Xu GM, Slunt HH, Gonzales V, Younkin LH, Younkin SG, Borchelt DR, Savonenko AV. (2005). Environmental enrichment mitigates cognitive deficits in a mouse model of Alzheimer’s disease. J Neurosci, 25, 5217–5224.
   PubMed Web of Science ®Google Scholar
• Janssen I, Boyce WF, Simpson K, Pickett W. (2006). Influence of individual – and area-level measures of socioeconomic status on obesity, unhealthy eating, and physical inactivity in Canadian adolescents. Am J Clin Nutr, 83, 139–145.
   PubMed Web of Science ®Google Scholar
• Kazantzis G, Smith MA, Grant LD, Sors AI (1989). Lead: ancient metal–modern menace. Lead Exposure and Child Development–An International Perspective (M.A., Smith, L.D. Grant, and A.I. Sors, eds.), Kluwer Academic Press, Boston, 119–128.
   Google Scholar
• Lasley SM, Green MC, Gilbert ME. (1999). Influence of exposure period on in vivo hippocampal glutamate and GABA release in rats chronically exposed to lead. Neurotoxicology, 20, 619–629.
   Google Scholar
• Lee S, Kawachi I, Berkman LF, Grodstein F. (2003). Education, other socioeconomic indicators, and cognitive function. Am J Epidemiol, 157, 712–720.
   PubMed Web of Science ®Google Scholar
• Lee VM, Goedert M, Trojanowski JQ. (2001). Neurodegenerative tauopathies. Annu Rev Neurosci, 24, 1121–1159.
   PubMed Web of Science ®Google Scholar
• Li N, Yu ZL, Wang L, Zheng YT, Jia JX, Wang Q, Zhu MJ, Liu XL, Xia X, Li WJ. (2010). Increased tau phosphorylation and beta amyloid in the hipocampus of mouse pups by early life lead exposure. Acta Biol Hung, 61, 123–134.
   Google Scholar
• Li YY, Chen T, Wan Y, Xu SQ. (2010). Lead exposure in pheochromocytoma cells induces persistent changes in amyloid precursor protein gene methylation patterns. Environ Toxicol. 2010 Nov 29 [Epub ahead of print]
   Google Scholar
• Liu F, Grundke-Iqbal I, Iqbal K, Gong CX. (2005). Contributions of protein phosphatases PP1, PP2A, PP2B and PP5 to the regulation of tau phosphorylation. Eur J Neurosci, 22, 1942–1950.
   PubMed Web of Science ®Google Scholar
• Liu Q, Zerbinatti CV, Zhang J, Hoe HS, Wang B, Cole SL, Herz J, Muglia L, Bu G. (2007). Amyloid precursor protein regulates brain apolipoprotein E and cholesterol metabolism through lipoprotein receptor LRP1. Neuron, 56, 66–78.
   PubMed Web of Science ®Google Scholar
• Luchsinger JA. (2010). Diabetes, related conditions, and dementia. J Neurol Sci, 299, 35–38.
   PubMed Web of Science ®Google Scholar
• Markesbery WR, Carney JM. (1999). Oxidative alterations in Alzheimer’s disease. Brain Pathol, 9, 133–146.
   PubMed Web of Science ®Google Scholar
• Miodovnik A, Landrigan PJ. (2009). The U.S. Food and Drug Administration risk assessment on lead in women’s and children’s vitamins is based on outdated assumptions. Environ Health Perspect, 117, 1021–1022.
   Google Scholar
• Moalem S, Percy ME, Andrews DF, Kruck TP, Wong S, Dalton AJ, Mehta P, Fedor B, Warren AC. (2000). Are hereditary hemochromatosis mutations involved in Alzheimer disease? Am J Med Genet, 93, 58–66.
   PubMed Web of Science ®Google Scholar
• Momcilovic B, Alkhatib HA, Duerre JA, Cooley M, Long WM, Harris TR, Lykken GI. (2001). Environmental lead-210 and bismuth-210 accrue selectively in the brain proteins in Alzheimer disease and brain lipids in Parkinson disease. Alzheimer Dis Assoc Disord, 15, 106–115.
   PubMed Web of Science ®Google Scholar
• Morris JC, Storandt M, Miller JP, McKeel DW, Price JL, Rubin EH, Berg L. (2001). Mild cognitive impairment represents early-stage Alzheimer disease. Arch Neurol, 58, 397–405.
   PubMed Web of Science ®Google Scholar
• Muldoon SB, Cauley JA, Kuller LH, Morrow L, Needleman HL, Scott J, Hooper FJ. (1996). Effects of blood lead levels on cognitive function of older women. Neuroepidemiology, 15, 62–72.
   PubMed Web of Science ®Google Scholar
• Mungarro-Menchaca X, Ferrera P, Morán J, Arias C. (2002). beta-Amyloid peptide induces ultrastructural changes in synaptosomes and potentiates mitochondrial dysfunction in the presence of ryanodine. J Neurosci Res, 68, 89–96.
   PubMed Web of Science ®Google Scholar
• Mutter J, Curth A, Naumann J, Deth R, Walach H. (2010). Does inorganic mercury play a role in Alzheimer’s disease? A systematic review and an integrated molecular mechanism. J Alzheimers Dis, 22, 357–374.
   PubMed Web of Science ®Google Scholar
• Nasreddine ZS, Phillips NA, Bédirian V, Charbonneau S, Whitehead V, Collin I, Cummings JL, Chertkow H. (2005). The Montreal Cognitive Assessment, MoCA: a brief screening tool for mild cognitive impairment. J Am Geriatr Soc, 53, 695–699.
   PubMed Web of Science ®Google Scholar
• Niklowitz WJ, Mandybur TI. (1975). Neurofibrillary changes following childhood lead encephalopathy. J Neuropathol Exp Neurol, 34, 445–455.
   PubMedGoogle Scholar
• Nordberg M, Winblad B, Fratiglioni L, Basun H. (2000). Lead concentrations in elderly urban people related to blood pressure and mental performance: results from a population-based study. Am J Ind Med, 38, 290–294.
   PubMed Web of Science ®Google Scholar
• Oortgiesen M, van Kleef RG, Bajnath RB, Vijverberg HP. (1990). Nanomolar concentrations of lead selectively block neuronal nicotinic acetylcholine responses in mouse neuroblastoma cells. Toxicol Appl Pharmacol, 103, 165–174.
   Google Scholar
• Ott A, Breteler MM, van Harskamp F, Claus JJ, van der Cammen TJ, Grobbee DE, Hofman A. (1995). Prevalence of Alzheimer’s disease and vascular dementia: association with education. The Rotterdam study. BMJ, 310, 970–973.
   PubMed Web of Science ®Google Scholar
• Patil AJ, Bhagwat VR, Patil JA, Dongre NN, Ambekar JG, Jailkhani R, Das KK. (2006). Effect of lead (Pb) exposure on the activity of superoxide dismutase and catalase in battery manufacturing workers (BMW) of Western Maharashtra (India) with reference to heme biosynthesis. Int J Environ Res Public Health, 3, 329–337.
   PubMedGoogle Scholar
• Payton M, Riggs KM, Spiro A 3rd, Weiss ST, Hu H. (1998). Relations of bone and blood lead to cognitive function: the VA Normative Aging Study. Neurotoxicol Teratol, 20, 19–27.
   PubMed Web of Science ®Google Scholar
• Petersen RC. (2004). Mild cognitive impairment as a diagnostic entity. J Intern Med, 256, 183–194.
   PubMed Web of Science ®Google Scholar
• Petersen RC, Negash S. (2008). Mild cognitive impairment: an overview. CNS Spectr, 13, 45–53.
   PubMed Web of Science ®Google Scholar
• Petersen RC, Smith GE, Waring SC, Ivnik RJ, Tangalos EG, Kokmen E. (1999). Mild cognitive impairment: clinical characterization and outcome. Arch Neurol, 56, 303–308.
   PubMed Web of Science ®Google Scholar
• Pulliam JF, Jennings CD, Kryscio RJ, Davis DG, Wilson D, Montine TJ, Schmitt FA, Markesbery WR. (2003). Association of HFE mutations with neurodegeneration and oxidative stress in Alzheimer’s disease and correlation with APOE. Am J Med Genet B Neuropsychiatr Genet, 119B, 48–53.
   Google Scholar
• Qiu WQ, Walsh DM, Ye Z, Vekrellis K, Zhang J, Podlisny MB, Rosner MR, Safavi A, Hersh LB, Selkoe DJ. (1998). Insulin-degrading enzyme regulates extracellular levels of amyloid beta-protein by degradation. J Biol Chem, 273, 32730–32738.
   PubMed Web of Science ®Google Scholar
• Querfurth HW, LaFerla FM. (2010). Alzheimer’s disease. N Engl J Med, 362, 329–344.
   PubMed Web of Science ®Google Scholar
• Quig D. (1998). Cysteine metabolism and metal toxicity. Altern Med Rev, 3, 262–270.
   PubMedGoogle Scholar
• Rabinowitz MB. (1991). Toxicokinetics of bone lead. Environ Health Perspect, 91, 33–37.
   PubMed Web of Science ®Google Scholar
• Rabinowitz MB, Wetherill GW, Kopple JD. (1976). Kinetic analysis of lead metabolism in healthy humans. J Clin Invest, 58, 260–270.
   PubMed Web of Science ®Google Scholar
• Rahman A, Brew BJ, Guillemin GJ. (2011). Lead dysregulates serine/threonine protein phosphatases in human neurons. Neurochem Res, 36, 195–204.
   PubMed Web of Science ®Google Scholar
• Reddy CC, Scholz RW, Massaro EJ. (1981). Cadmium, methylmercury, mercury, and lead inhibition of calf liver glutathione S-transferase exhibiting selenium-independent glutathione peroxidase activity. Toxicol Appl Pharmacol, 61, 460–468.
   PubMed Web of Science ®Google Scholar
• Rehman SU (1984). Lead-induced regional lipid peroxidation in brain. Toxicol Lett, 21, 333–337.
   PubMed Web of Science ®Google Scholar
• Reinhard C, Hébert SS, De Strooper B. (2005). The amyloid-beta precursor protein: integrating structure with biological function. EMBO J, 24, 3996–4006.
   PubMed Web of Science ®Google Scholar
• Rogers JT, Randall JD, Cahill CM, Eder PS, Huang X, Gunshin H, Leiter L, McPhee J, Sarang SS, Utsuki T, Greig NH, Lahiri DK, Tanzi RE, Bush AI, Giordano T, Gullans SR. (2002). An iron-responsive element type II in the 59-untranslated region of the Alzheimer’s amyloid precursor protein transcript. J Biol Chem, 277, 45518–45528.
   PubMed Web of Science ®Google Scholar
• Sanders T, Liu Y, Buchner V, Tchounwou PB. (2009). Neurotoxic effects and biomarkers of lead exposure: a review. Rev Environ Health, 24, 15–45.
   PubMedGoogle Scholar
• Schwartz BS, Stewart WF. (2007). Lead and cognitive function in adults: a questions and answers approach to a review of the evidence for cause, treatment, and prevention. Int Rev Psychiatry, 19, 671–692.
   PubMed Web of Science ®Google Scholar
• Selkoe DJ. (2001). Alzheimer’s disease: genes, proteins, and therapy. Physiol Rev, 81, 741–766.
   PubMed Web of Science ®Google Scholar
• Selkoe DJ. (2002). Alzheimer’s disease is a synaptic failure. Science, 298, 789–791.
   PubMed Web of Science ®Google Scholar
• Silbergeld EK, Schwartz J, Mahaffey K. (1988). Lead and osteoporosis: mobilization of lead from bone in postmenopausal women. Environ Res, 47, 79–94.
   PubMed Web of Science ®Google Scholar
• Silbergeld EK. (1992). Mechanisms of lead neurotoxicity, or looking beyond the lamppost. FASEB J, 6, 3201–3206.
   PubMed Web of Science ®Google Scholar
• Snyder EM, Nong Y, Almeida CG, Paul S, Moran T, Choi EY, Nairn AC, Salter MW, Lombroso PJ, Gouras GK, Greengard P. (2005). Regulation of NMDA receptor trafficking by amyloid-beta. Nat Neurosci, 8, 1051–1058.
   PubMed Web of Science ®Google Scholar
• Somashekaraiah BV, Padmaja K, Prasad AR. (1992). Lead-induced lipid peroxidation and antioxidant defense components of developing chick embryos. Free Radic Biol Med, 13, 107–114.
   PubMed Web of Science ®Google Scholar
• Stewart WF, Schwartz BS, Simon D, Kelsey K, Todd AC. (2002). ApoE genotype, past adult lead exposure, and neurobehavioral function. Environ Health Perspect, 110, 501–505.
   PubMed Web of Science ®Google Scholar
• Tong S, von Schirnding YE, Prapamontol T. (2000). Environmental lead exposure: a public health problem of global dimensions. Bull World Health Organ, 78, 1068–1077.
   PubMed Web of Science ®Google Scholar
• Toscano CD, Guilarte TR. (2005). Lead neurotoxicity: from exposure to molecular effects. Brain Res Brain Res Rev, 49, 529–554.
   PubMed Web of Science ®Google Scholar
• Tsai MS, Tangalos EG, Petersen RC, Smith GE, Schaid DJ, Kokmen E, Ivnik RJ, Thibodeau SN. (1994). Apolipoprotein E: risk factor for Alzheimer disease. Am J Hum Genet, 54, 643–649.
   PubMed Web of Science ®Google Scholar
• US Census Bureau. (2000). National Population Projections-Summary Tables 1998–2000 [Online]. Available: http://www.census.gov/population/www/projections/natsum-T3.html [Accessed September 02, 2010].
   Google Scholar
• van Praag H, Kempermann G, Gage FH. (2000). Neural consequences of environmental enrichment. Nat Rev Neurosci, 1, 191–198.
   PubMed Web of Science ®Google Scholar
• Van Wijngaarden E, Winters PC, Cory-Slechta DA. (2011). Blood lead levels in relation to cognitive function in older U.S. adults. Neurotoxicology, 32, 110–115.
   Google Scholar
• Van Wijngaarden E, Campbell JR, Cory-Slechta DA (2009). Bone lead levels are associated with measures of memory impairment in older adults. Neurotoxicology, 30, 572–580.
   Google Scholar
• Venti A, Giordano T, Eder P, Bush AI, Lahiri DK, Greig NH, Rogers JT. (2004). The integrated role of desferrioxamine and phenserine targeted to an iron-responsive element in the APP-mRNA 59-untranslated region. Ann N Y Acad Sci, 1035, 34–48.
   Google Scholar
• Verghese PB, Castellano JM, Holtzman DM. (2011). Apolipoprotein E in Alzheimer’s disease and other neurological disorders. Lancet Neurol, 10, 241–252.
   PubMed Web of Science ®Google Scholar
• Verina T, Rohde CA, Guilarte TR. (2007). Environmental lead exposure during early life alters granule cell neurogenesis and morphology in the hippocampus of young adult rats. Neuroscience, 145, 1037–1047.
   PubMed Web of Science ®Google Scholar
• Villeda-Hernández J, Barroso-Moguel R, Méndez-Armenta M, Nava-Ruíz C, Huerta-Romero R, Ríos C. (2001). Enhanced brain regional lipid peroxidation in developing rats exposed to low level lead acetate. Brain Res Bull, 55, 247–251.
   Google Scholar
• Waldron HA. (1973). Lead poisoning in the ancient world. Med Hist, 17, 391–399.
   PubMedGoogle Scholar
• Wang FT, Hu H, Schwartz J, Weuve J, Spiro AS, Sparrow D, Nie H, Silverman EK, Weiss ST, Wright RO. (2007). Modifying effects of the HFE polymorphisms on the association between lead burden and cognitive decline. Environ Health Perspect, 115, 1210–1215.
   PubMed Web of Science ®Google Scholar
• Wang L, Luo L, Luo YY, Gu Y, Ruan DY. (2007). Effects of Pb2+ on muscarinic modulation of glutamatergic synaptic transmission in rat hippocampal CA1 area. Neurotoxicology, 28, 499–507.
   Google Scholar
• Wechsler D. (1997). Wechsler adult intelligence scale-III (WAIS-III), San Antonio, TX, Harcourt Brace and Company.
   Google Scholar
• Weisskopf MG, Wright RO, Schwartz J, Spiro A 3rd, Sparrow D, Aro A, Hu H. (2004). Cumulative lead exposure and prospective change in cognition among elderly men: the VA Normative Aging Study. Am J Epidemiol, 160, 1184–1193.
   PubMed Web of Science ®Google Scholar
• Weisskopf MG, Proctor SP, Wright RO, Schwartz J, Spiro A 3rd, Sparrow D, Nie H, Hu H. (2007). Cumulative lead exposure and cognitive performance among elderly men. Epidemiology, 18, 59–66.
   PubMed Web of Science ®Google Scholar
• Weuve J, Korrick SA, Weisskopf MG, Weisskopf MA, Ryan LM, Schwartz J, Nie H, Grodstein F, Hu H. (2009). Cumulative exposure to lead in relation to cognitive function in older women. Environ Health Perspect, 117, 574–580.
   Google Scholar
• White RF, Diamond R, Proctor S, Morey C, Hu H. (1993). Residual cognitive deficits 50 years after lead poisoning during childhood. Br J Ind Med, 50, 613–622.
   PubMedGoogle Scholar
• Whitmer RA, Karter AJ, Yaffe K, Quesenberry CP Jr, Selby JV. (2009). Hypoglycemic episodes and risk of dementia in older patients with type 2 diabetes mellitus. JAMA, 301, 1565–1572.
   PubMed Web of Science ®Google Scholar
• Wright RO, Tsaih SW, Schwartz J, Spiro A 3rd, McDonald K, Weiss ST, Hu H. (2003). Lead exposure biomarkers and mini-mental status exam scores in older men. Epidemiology, 14, 713–718.
   PubMed Web of Science ®Google Scholar
• Wu J, Basha MR, Brock B, Cox DP, Cardozo-Pelaez F, McPherson CA, Harry J, Rice DC, Maloney B, Chen D, Lahiri DK, Zawia NH. (2008). Alzheimer’s disease (AD)-like pathology in aged monkeys after infantile exposure to environmental metal lead (Pb): evidence for a developmental origin and environmental link for AD. J Neurosci, 28, 3–9.
   PubMed Web of Science ®Google Scholar
• Yun SW, Hoyer S. (2000). Effects of low-level lead on glycolytic enzymes and pyruvate dehydrogenase of rat brain in vitro: relevance to sporadic Alzheimer’s disease? J Neural Transm, 107, 355–368.
   PubMed Web of Science ®Google Scholar
• Zawia NH, Sharan R, Brydie M, Oyama T, Crumpton T. (1998). Sp1 as a target site for metal-induced perturbations of transcriptional regulation of developmental brain gene expression. Brain Res Dev Brain Res, 107, 291–298.
   PubMedGoogle Scholar
• Zhao Q, Slavkovich V, Zheng W. (1998). Lead exposure promotes translocation of protein kinase C activities in rat choroid plexus in vitro, but not in vivo. Toxicol Appl Pharmacol, 149, 99–106.
   PubMed Web of Science ®Google Scholar
• Zlokovic BV, Deane R, Sagare AP, Bell RD, Winkler EA. (2010). Low-density lipoprotein receptor-related protein-1: a serial clearance homeostatic mechanism controlling Alzheimer’s amyloid ß-peptide elimination from the brain. J Neurochem, 115, 1077–1089.
   PubMed Web of Science ®Google Scholar